Clinical Trials Directory

Trials / Terminated

TerminatedNCT00470093

Interferon Alfa and Interleukin-6 in Treating Patients With Recurrent Multiple Myeloma

A Pilot Study of Differentiation Therapy in Multiple Myeloma Using Interleukin-6 and Interferon-a

Status
Terminated
Phase
EARLY_Phase 1
Study type
Interventional
Enrollment
3 (actual)
Sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Academic / Other
Sex
All
Age
18 Years – 120 Years
Healthy volunteers
Not accepted

Summary

RATIONALE: Interferon alfa may interfere with the growth of cancer cells. Interleukin-6 may stimulate the white blood cells to kill cancer cells. Giving interferon alfa together with interleukin-6 may kill more cancer cells. PURPOSE: This clinical trial is studying the side effects and how well giving interferon alfa together with interleukin-6 works in treating patients with recurrent multiple myeloma.

Detailed description

OBJECTIVES: * Determine the response rate in patients with recurrent multiple myeloma treated with recombinant interferon alfa and recombinant interleukin-6. * Determine the safety and optimal dose of this regimen in these patients. * Determine the toxicity of this regimen in these patients. * Determine the impact of this regimen on clonogenic growth of myeloma cells in serial in vitro assays. OUTLINE: This is a pilot study. Patients receive recombinant interferon alfa subcutaneously (SC) once daily. Beginning 1 month later, patients also receive recombinant interleukin-6 SC once daily. Treatment continues for up to 6 months in the absence of disease progression or unacceptable toxicity. PROJECTED ACCRUAL: A total of 27 patients will be accrued for this study.

Conditions

Interventions

TypeNameDescription
BIOLOGICALrecombinant interferon-α
BIOLOGICALrecombinant interleukin-6

Timeline

Start date
2007-10-01
Primary completion
2010-01-01
Completion
2010-01-01
First posted
2007-05-07
Last updated
2018-11-16
Results posted
2018-11-16

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00470093. Inclusion in this directory is not an endorsement.